Petrelintide in 2026: The "Gentler" Weight Loss Drug Posting 10% Weight Loss With Almost No Nausea

Petrelintide's full Phase 2 results — from the 485-person ZUPREME-1 trial — were published in The Lancet Diabetes & Endocrinology and presented at the European Association for the Study of Diabetes (EASD) annual meeting on September 30, 2026. The headline finding, now making the rounds in consumer health coverage: a drug that produces meaningful weight loss while being noticeably easier on the stomach than the GLP-1 class.

Unlike semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), petrelintide is not a GLP-1 medication at all. It mimics amylin, a different hormone released by the pancreas alongside insulin. Amylin slows stomach emptying, promotes fullness, and appears to work on satiety signals in the brain through a separate pathway. Roche considered the mechanism promising enough to pay $1.65 billion upfront in 2025 to partner with Zealand Pharma on it.

ZUPREME-1 enrolled 485 adults with overweight or obesity (average BMI around 36.7) and tested five once-weekly doses of petrelintide against placebo over 42 weeks. The results:

Weight loss reached up to 10.2% at 42 weeks on the treatment policy estimand (up to 10.7% on the efficacy estimand), versus roughly 1.4–1.7% for placebo. Interestingly, the mid-range 5 mg dose performed about as well as the highest 9 mg dose — at the 28-week primary endpoint, 5 mg produced 9.8% mean weight loss versus 9.3–9.4% for the higher doses, according to the trial data. That plateau matters: it suggests patients may get petrelintide's full benefit without pushing to high doses, which is typically where side effects pile up.

To put 10% in context: that's less than the roughly 15% seen with semaglutide 2.4 mg or the 20%+ seen with tirzepatide in their trials — but it's a Phase 2 result at 42 weeks, and it lands squarely in the range where health benefits like improved blood pressure, blood sugar, and joint load become meaningful.

Efficacy wasn't why this trial made headlines. Tolerability was.

In ZUPREME-1, gastrointestinal adverse events were generally mild and occurred at rates close to placebo. Nausea was reported by about 20% of petrelintide patients versus 6% on placebo — compared with the 40–60% nausea rates commonly seen in GLP-1 trials. Vomiting and diarrhea occurred at rates the same as or lower than placebo, and at the maximally effective dose there were zero cases of vomiting and zero discontinuations due to GI side effects.

For patients, that profile could matter in two ways. First, a meaningful share of people simply cannot stay on GLP-1s because of nausea — and the medication only works if you can keep taking it. Second, gentler titration could mean fewer of the food aversions and eating disruptions that make the first months of GLP-1 therapy difficult. If nausea has been your sticking point, it's also worth knowing that anti-nausea support is already available alongside today's GLP-1 treatments — you don't have to wait years for a new drug class to get help with tolerability.

Amylin is quickly becoming the most interesting corner of obesity medicine, and petrelintide isn't the only contender. Novo Nordisk's CagriSema pairs an amylin analog with semaglutide, and Eli Lilly's eloralintide — both alone and combined with tirzepatide as EloraTZP — posted strong results this year (we covered the 23% EloraTZP data here and the CagriSema results here).

Petrelintide's bet is different: amylin alone, aimed at people who want solid — not record-breaking — weight loss with an easier ride. Zealand and Roche have already launched the global Phase 3 ZUPREME program, with registrational trials in obesity, obesity with type 2 diabetes, and obesity with cardiovascular disease, and a combination trial pairing petrelintide with a GLP-1 partner molecule planned as well. Phase 3 primary completions are expected around late 2028, which puts a realistic FDA decision in the 2029–2030 window. Petrelintide is investigational: it is not FDA-approved, and Phase 3 results could land higher or lower than Phase 2.

The honest takeaway: petrelintide is a promising reason for optimism, not a reason to wait three or more years. Proven options exist today, and the right choice depends on your health history, goals, and how your body handles each medication — a decision to make with a licensed provider.

If you've tried a GLP-1 and struggled with nausea, there are evidence-based moves available right now: slower dose titration, switching between semaglutide and tirzepatide (many patients tolerate one better than the other), prescription anti-nausea medication, and dietary adjustments in the first weeks. GLP-1 medications also carry screening considerations — they aren't recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, or during pregnancy — which is exactly why treatment should start with a real medical review rather than a coupon code.

JoeyMed's weight loss program connects you with a licensed provider who reviews your health history, helps you choose between today's proven GLP-1 options like semaglutide and tirzepatide, and manages your dosing over time — including tolerability support such as titration adjustments and anti-nausea medication when you need it. Treatment ships discreetly to your door, and your provider stays available as new options like petrelintide move through trials. If you've been waiting for a weight loss plan that takes side effects as seriously as results, you can start your online visit today.